Pharmacologic treatment of anorexia nervosa: Where do we go from here?

International Journal of Eating Disorders

Volumn 37, Issue SUPPL., 2005, Pages

  Attia, Evelyn ^a   Schroeder, Laura ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Anorexia nervosa; Eating disorders; Medication; Pharmacology; Review

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CHLORPROMAZINE; CISAPRIDE; CLOMIPRAMINE; CYPROHEPTADINE; DIAZEPAM; FLUOXETINE; LITHIUM; MINERAL; NALOXONE; NALTREXONE; NEUROLEPTIC AGENT; OIL; OLANZAPINE; OPIATE ANTAGONIST; PIMOZIDE; PLACEBO; PROKINETIC AGENT; SEROTONIN UPTAKE INHIBITOR; SULPIRIDE; TETRAHYDROCANNABINOL; TRYPTOPHAN; VITAMIN; ZINC;

ANOREXIA NERVOSA; ANXIETY DISORDER; BODY BUILD; BODY WEIGHT; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DISEASE EXACERBATION; HUMAN; MEDICAL LITERATURE; MEDLINE; OBSESSION; PARANOIA; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SEIZURE; SIDE EFFECT; SLEEP DISORDER; TORSADE DES POINTES; UNDERWEIGHT; WEIGHT GAIN;

ANOREXIA NERVOSA; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; GASTROINTESTINAL AGENTS; HUMANS; NARCOTIC ANTAGONISTS;

EID: 18044380280     PISSN: 02763478     EISSN: None     Source Type: Journal    
DOI: 10.1002/eat.20133     Document Type: Review

References (31)

1. Sullivan PF. Mortality in anorexia nervosa. Am J Psychiatry 1995;152(7):1073.
2. Dally P, Sargant W. A new treatment of anorexia nervosa. Br Med J 1960;1:1970.
3. Vandereycken W, Pierloot R. Pimozide combined with behavior therapy in the short-term treatment of anorexia nervosa. Acta Psychiatr Scand 1982;66:445.
4. Vandereycken W. Neuroleptics in the short-term treatment of anorexia nervosa: a double-blind placebo-controlled study with sulpiride. Br J Psychiatry 1984;144:288.
5. Jensen VS, Mejlhede A. Anorexia nervosa: treatment with olanzapine. Br J Psychiatry 2000;177:87.
6. La Via MC, Gray N, Kaye WH. Case reports of olanzapine treatment of anorexia nervosa. Int J Eat Disord 2000;27(3):363.
7. Hansen L. Olanzapine in the treatment of anorexia nervosa. Br J Psychiatry 1999;175:592.
8. Powers PS, Santana CA, Bannon YS. Olanzapine in the treatment of anorexia nervosa: an open label trial. Int J Eat Disord 2002;32(2):146.
9. Lacey JH, Crisp AH. Hunger, food intake and weight: the impact of clomipramine on a refeeding anorexia nervosa population. Postgrad Med J 1980;56(Suppl 1):79.
10. Biederman J, Herzog DB, Rivinus TM, et al. Amitriptyline in the treatment of anorexia nervosa: a double-blind, placebo-controlled study. J Clin Psychopharmacol 1985;5:10.
11. Halmi KA, Eckert ED, LaDu TJ, et al. Anorexia nervosa: treatment efficacy of cyproheptadine and amitriptyline. Arch Gen Psychiatry 1986;43:177.
12. Fluoxetine Bulimia Nervosa Collaborative Study Group. Fluoxetine in the treatment of bulimia nervosa: a multicenter, placebo-controlled, double-blind trial. Arch Gen Psychiatry 1992; 49:139.
13. Attia E, Haiman C, Walsh BT, et al. Does fluoxetine augment the inpatient treatment of anorexia nervosa? Am J Psychiatry 1998;155(4):548.
14. Kaye W, Gendall K, Strober M. Serotonin neuronal function and selective serotonin reuptake inhibitor treatment in anorexia and bulimia nervosa. Biol Psychiatry 1998; 44(9):825.
15. Barbarich NC, McConaha CW, Halmi KA, et al. Use of nutritional supplements to increase efficacy of fluoxetine in the treatment of anorexia nervosa. Int J Eat Disord 2004;35:10.
16. Kaye WH, Weltzin TE, Hsu G, et al. An open trial of fluoxetine in patients with anorexia nervosa. J Clin Psychiatry 1991;52(11):464.
17. Kaye WH, Weltzin TE, Hsu G, et al. Relapse prevention with fluoxetine in anorexia nervosa: a double-blind placebo-controlled study. Washington, DC: American Psychiatric Association, 1997; p 178.
18. Strober M, Freeman R, DeAntonio M, et al. Does adjunctive fluoxetine influence the post-hospital course of restrictor-type anorexia nervosa? A 24-month prospective, longitudinal followup and comparison with historical controls. Psychopharmacol Bull 1997;33(3):425.
19. Stacher G, Abatzi TA, Wiesnagrotzki S, et al. Gastric emptying, body weight and symptoms in primary anorexia nervosa: long term effects of cisapride. Br J Psychiatry 1993; 162:398.
20. Szmukler G, Young GP, Miller G, et al. A controlled trial of cisapride in anorexia nervosa. Int J Eat Disord 1995;17(4):347.
21. Kaye WH. Opioid antagonist drugs in the treatment of anorexia nervosa. The role of drug treatments for eating disorders. New York: Brummer/Mazel; 2002. p 150.
22. Marrazzi MA, Bacon JP, Kinzie J, et al. Naltrexone use in the treatment of anorexia nervosa and bulimia nervosa. Int Clin Psychopharmacol 1995;10(3):163.
23. Gross HA, Ebert MH, Faden VB, et al. A double-blind controlled trial of lithium carbonate in primary anorexia nervosa. J Clin Psychopharmacol 1981;1:376.
24. Vigersky RA, Loriaux DL. The effect of cyproheptadine in anorexia nervosa: a double-blind trial. In: Vigersky RA, editor. Anorexia nervosa. New York: Raven Press; 1977. p 349.
25. Goldberg SC, Halmi KA, Eckert ED, et al. Cyproheptadine in anorexia nervosa. Br J Psychiatry 1979;134:67.
26. Gross HA, Ebert MH, Faden VB, et al. A double-blind trial of delta9-tetrahydrocannabinol in primary anorexia nervosa. J Clin Psychopharmacol 1983;3:165.
27. Katz RL, Keen CL, Litt IF, et al. Zinc deficiency in anorexia nervosa. J Adolesc Health Care 1987;8:400.
28. Birmingham CL, Goldner EM, Bakan R. Controlled trial of zinc supplementation in anorexia nervosa. Int J Eat Disord 1994;15:251.
29. Lask B, Fosson A, Rolfe U, et al. Zinc deficiency and childhood-onset anorexia nervosa. J Clin Psychiatry 1993;54(2):63.
30. Sunday SR, Halmi KA. Micro- and macroanalyses of patterns within a meal in anorexia and bulimia nervosa. Appetite 1996;26:21.
31. Pollice C, Kaye WH, Greeno CG, et al. Relationship of depression, anxiety, and obsessionality to state of illness in anorexia nervosa. Int J Eat Disord 1997;21(4):367.